A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy

Who May Qualify: - Has onset of seizures prior to 3 months of age. - Has a minimum weight of at least 10 kg at screening. - Has a documented SCN2A variant through genetic testing obtained via a laboratory accredited per Clinical Laboratory Improvement Amendments (CLIA) or College of American Pathologists (CAP) or equivalent. - Additional inclusion criteria apply and will be assessed by the study team Who Should NOT Join This Trial: - Has any clinically significant or known pathogenic genetic variant other than in the SCN2A gene, or a genetic variant that may explain or contribute to the participant's epilepsy and/or developmental disorder. - Is taking more than 2 sodium channel blocking anti-seizure medications - Additional exclusion criteria apply and will be assessed by the study team Always talk to your doctor about whether this trial is right for you.